John D Roberts MD

Professor of Medicine (Medical Oncology); Medical Director, Adult Sickle Cell Program at Yale-New Haven Hospital

Specialties & Subspecialties

Cancer Center, Yale: Prostate and Urologic Cancers Program | Hematology Program

Medical Oncology

Education & Training

  • M.D., University of Pennsylvania (1976)
  • AB, Harvard University (1982)
  • Resident, University of North Carolina at Chapel Hill , Internal Medicine and Pediatrics (1976 - 1980)
  • Fellow, University of Vermont , Medical Oncology (1982 - 1984)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

sickle cell disease; medical oncology phase I trials; urological cancers (prostate, bladder, testicle)


Cancers Treated

Bladder, Prostate, Testes (including Penis)


Board Certifications

  • Hospice & Palliative Medicine, Board Certified (2012)
  • Internal Medicine, Board Certified (1980)
  • Medical Oncology, Board Certified (1985)

Clinical Trials

ConditionsStudy Title
ProstatePhase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with metastatic castration resistant prostate cancer maintained on androgen deprivation therapy
Bladder, Breast - Female, Colon, Lung, Melanoma, skin, Other Endocrine System, Other Respiratory and Intrathoracic Organs, Other Urinary, Ovary, Rectum, and StomachA Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
Bladder, Breast - Female, Breast - Male, Colon, Kidney, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Skin, Other Urinary, Pancreas, Prostate, Small Intestine, and StomachA Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects with Advanced Tumors
Bladder, Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Breast - Female, Colon, Esophagus, Kidney, Liver, Lung, Melanoma, skin, and PancreasA Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors

More Clinical Trials...

Edit Profile